AMG-108
As of the edition of 20 October 2026, AMG-108 is a drug: went quiet in 2008; acts on IL1R1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2008
- Kind
- Unknown
- Registered trials
- 2, 0 stopped early
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL1R1 | Interleukin-1 receptor type 1 | P14778 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Amgen | Lead sponsor of trials | 2006 to now |